Q2 2025 Jazz Pharmaceuticals PLC Earnings Call Transcript
Key Points
- Jazz Pharmaceuticals PLC (JAZZ) reported over $1 billion in total revenue for Q2 2025, driven by strong performance in its neuroscience assets.
- Xywav sales increased by 13% year-over-year, with significant net patient additions in both narcolepsy and idiopathic hypersomnia.
- Epidiolex continues to show strong demand and is expected to reach blockbuster status this year.
- The company is optimistic about the potential approval of dordaviprone and Zepzelca, which could drive future growth.
- Jazz Pharmaceuticals PLC (JAZZ) has a robust pipeline with promising data from ongoing clinical trials, including Zepzelca and zanidatamab.
- The oncology portfolio faced near-term headwinds, with a 1% decrease in total oncology product sales compared to Q2 2024.
- Rylaze sales decreased by 7% year-over-year due to changes in pediatric ALL treatment protocols.
- Zepzelca sales decreased by 8% year-over-year, impacted by increased competition and changes in treatment patterns.
- The company revised its financial guidance, lowering the top end of its revenue range due to potential upside being less likely.
- There are concerns about the impact of potential multisource oxybate generics entering the market by the end of 2025.
Good day, and thank you for standing by. Welcome to Jazz Pharmaceuticals 2025 second-quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jack Spinks, Executive Director of Investor Relations.
Thank you, operator, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported at the second-quarter 2025 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors should also refer to the press release we issued earlier today that is available on our website. On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, President and Chief Operating Officer and recently announced Chief Executive Officer effective August 11; Robi Iannone, Executive Vice President, Global Head of R&D and Chief Medical Officer; and Phil Johnson, Executive Vice
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
